Alverin60 mg

Alverin is an antispasmodic used for the symptomatic relief of pain and spasm associated with the following conditions:

• Irritable bowel syndrome (IBS): Relief of abdominal pain, cramping, and bloating associated with IBS (established/guideline-supported use).
• Painful diverticular disease of the colon: Relief of colonic smooth muscle spasm and associated pain (established use).
• Primary dysmenorrhoea: Symptomatic relief of painful uterine cramping during menstruation (established use).

Alverin provides symptomatic relief of smooth muscle spasm only; it does not treat the underlying cause of abdominal or pelvic pain. Persistent, severe, or atypical symptoms (especially new-onset symptoms in patients over 40 years, or symptoms accompanied by rectal bleeding, unexplained weight loss, anaemia, fever, or a change in bowel habit) require prompt medical evaluation to exclude more serious underlying pathology before or during use of Alverin.

Each tablet/capsule of Alverine Citrate available in Bangladesh typically contains Alverine Citrate 60 mg as the active ingredient. Some international formulations are also available as 120 mg capsules, or in combination with simeticone for additional relief of flatulence. Excipients vary by manufacturer.

Alverin is a musculotropic (direct-acting) smooth muscle relaxant belonging to the antispasmodic class of medicines. Unlike anticholinergic antispasmodics, it acts directly on the smooth muscle of the gastrointestinal tract and uterus rather than through blockade of muscarinic receptors, which gives it a relatively favourable side-effect profile with minimal anticholinergic (dry mouth, blurred vision) effects at therapeutic doses.

Alverin is widely marketed in Bangladesh as an oral tablet (commonly 60 mg strength) for symptomatic relief of gastrointestinal and uterine smooth muscle spasm.

Mechanism of Action

Alverine Citrate exerts a direct musculotropic (papaverine-like) spasmolytic effect on the smooth muscle of the gastrointestinal tract and uterus. It is believed to act, at least in part, by modulating calcium ion movement across the smooth muscle cell membrane, thereby reducing hypermotility, spasm, and colonic/uterine muscle contraction. At therapeutic doses, Alverine Citrate has little to no clinically significant effect on cardiac or vascular smooth muscle, and it lacks significant anticholinergic or antihistaminic activity.

Pharmacokinetics

Alverine Citrate is absorbed from the gastrointestinal tract after oral administration and is metabolised in the body with subsequent elimination, predominantly renal, of its metabolites. Detailed pharmacokinetic data (e.g., precise bioavailability, protein binding, half-life) are not extensively characterised in the public literature.

No well-established, clinically significant drug interactions have been documented for Alverin in the available literature. However, as with any medicine, patients should inform their physician or pharmacist of all other medicines (prescription, over-the-counter, and herbal) they are taking before starting Alverin, particularly other antispasmodic or centrally-acting agents, so that the physician can monitor for any unexpected additive effects.

Alverin is generally well tolerated. Reported adverse effects include:

• Common: Nausea, headache, dizziness, pruritus (itching), and skin rash.
• Rare: Hypersensitivity reactions including anaphylaxis and dyspnoea (shortness of breath).
• Very rare: Hepatitis with jaundice has been reported; discontinue Alverin and seek medical advice promptly if yellowing of the skin/eyes, dark urine, or unexplained abdominal pain occurs.

Patients should seek immediate medical attention if signs of a severe allergic reaction (facial/throat swelling, severe rash, difficulty breathing) occur after taking Alverin.

Safety data for Alverin in human pregnancy and lactation are limited. Use of Alverin during pregnancy is generally not recommended, and it should be used only if clearly needed and the potential benefit justifies the potential risk to the fetus, under medical supervision.

Similarly, use of Alverin during breastfeeding is not recommended in the absence of adequate safety data; a physician should be consulted before use in breastfeeding mothers.

Alverin provides symptomatic relief only and does not treat the underlying cause of abdominal or pelvic pain. Medical evaluation is advised before starting Alverin, or promptly during treatment, in patients who:

• Are over 40 years of age with new-onset abdominal symptoms.
• Have rectal bleeding, unexplained weight loss, loss of appetite, or pallor (possible anaemia).
• Have persistent vomiting, fever, or a recent history of foreign travel.
• Have abnormal vaginal bleeding or new urinary symptoms.
• Do not experience improvement of symptoms within two weeks of starting Alverin.

These features may indicate a more serious underlying condition (e.g., inflammatory bowel disease, colorectal disease, or gynaecological pathology) that requires specific diagnosis and treatment rather than symptomatic therapy with Alverin alone.

Overdose with Alverin may cause hypotension (low blood pressure) and atropine-like toxic effects. Very high doses have rarely been associated with fatal outcomes in reported cases.

There is no specific antidote for Alverin overdose. In case of suspected overdose, seek immediate medical attention or contact the nearest emergency department/poison control service. Treatment is supportive and symptomatic, based on clinical assessment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric: Use of Alverin is not recommended in children below 12 years of age, as safety and efficacy have not been established in this age group.

Elderly: No specific dose adjustment is required; standard adult dosing is generally used, with routine clinical monitoring.

Renal impairment: No well-established dose-adjustment data exist; use with routine caution.

Hepatic impairment: Use with caution given rare reports of hepatitis; monitor for signs of liver dysfunction.

Pregnancy and lactation: See Pregnancy and Lactation section above.